This webcast features: Jan Van Hauwermeiren, VP Sales and Marketing, Ovizio Imaging Systems

Cell-based technology is a fundamental pillar of modern biotechnology. With the development of cell therapy products (CTPs), there is an increased need for robust and validated measurements for cell characterization to enable manufacturing control and a safe, high-quality product released to the patients.

Our company has developed an inline, automated microscope that generates reliable viable cell counts (VCCs) without the need for active sampling, in real time and without any labelling. Its versatility makes it compatible with off-the-shelf stirred tanks, rocking-motion bags and others, including static vessels.

The cell characterization and quantification are based on Ovizio’s patented Double Differential Digital Holographic Microscopy (D3HM) technology. The microscope generates a holographic fingerprint based on 70 parameters for every cell that is imaged and feeds to a machine learning platform. Fast and accurate, the algorithms automatically discriminate between different cellular statuses (live, dead, activated, etc.), give access to in-depth quality attributes and dynamic properties of your cell culture, and may also provide additional information on a single cell level.

This webinar illustrates the capability of the technology to continuously monitor inline the CAR-T cells expansion process without any need for open handling. Our microscope delivers an accurate count of all cell populations, regardless of the status. The counts have been proven to be strongly comparable with offline references. In addition, the specificity of the holographic fingerprint allows to detect potential contaminants (such as beads or contaminating cells) before they become an issue in the product formulation, saving time and cost in case of a faulty batch. Furthermore, our technology can be used for quality control of the formulated product before it is released to the patient.

Watch the recorded webcast below.